Loading...
Drug Pricing Investigation
House Committee on Oversight and Reform
House Committee on Oversight and Reform
Abstract
This report summarizes the findings of a nearly three-year investigation by the Committee on Oversight and Reform into pricing and business practices for branded prescription drugs in the United States. The investigation focused on ten companies selling 12 drugs with high costs to the Medicare program. The investigation reveals unsustainable, unjustified, and unfair pricing practices that strain the U.S. healthcare system and leave millions unable to afford essential medications. The report includes insights into tactics used by drug companies, such as suppressing competition, and highlights the impact of high drug prices on patients and federal healthcare programs.
Date
2021-12-10
Document Type
House Majority Staff Report
Serial Number
Document Length
269 pages
Congress
117
Relation
DOI
Keywords
Staff Reports, House, Democratic
PAP Major Code
3: Health
PAP Minor Code
335: Prescription Drug Coverage and Costs
Related Hearings
• House Committee on Oversight and Reform, hearing on "Examining the Actions of Drug Companies in Raising Prescription Drug Prices," 116th Cong., H.Hrg. 116-01, (2019, January 29)
• House Committee on Oversight and Reform, hearing on "The Patient Perspective: The Devastating Impacts of Skyrocketing Drug Prices on American Families," 116th Cong., H.Hrg. 116-55, (2019, July 26)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Part I)," 116th Cong., H.Hrg. 116-122, (2020, September 30)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Part II)," 116th Cong., H.Hrg. 116-123, (2020, October 1)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices (Part III): Testimony from AbbVie CEO Richard Gonzalez," 117th Cong., H.Hrg. 117-22, (2021, May 18)
• House Committee on Oversight and Reform, hearing on "The Patient Perspective: The Devastating Impacts of Skyrocketing Drug Prices on American Families," 116th Cong., H.Hrg. 116-55, (2019, July 26)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Part I)," 116th Cong., H.Hrg. 116-122, (2020, September 30)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Part II)," 116th Cong., H.Hrg. 116-123, (2020, October 1)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices (Part III): Testimony from AbbVie CEO Richard Gonzalez," 117th Cong., H.Hrg. 117-22, (2021, May 18)